Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Research and collaboration revenue	$ 43	$ 9	$ 683	$ 203
Operating expenses
Research and development	19,622	11,735	55,302	29,412
General and administrative	8,716	2,317	21,998	6,885
Total operating expenses	28,338	14,052	77,300	36,297
Loss from operations	(28,295)	(14,043)	(76,617)	(36,094)
Other income (expense), net:
Interest income, net	7,892	2,283	20,379	4,100
Other (expense) income, net:	(2)	(8)	(3)	(58)
Total other income (expense), net	7,890	2,275	20,376	4,042
Net loss and comprehensive loss	(20,405)	(11,768)	(56,241)	(32,052)
Deemed dividend on redeemable convertible preferred stock issuances		(410)		(410)
Cumulative redeemable convertible preferred stock dividends	0	(5,336)	0	(12,846)
Net loss attributable to common stockholders	$ (20,405)	$ (17,514)	$ (56,241)	$ (45,308)
Net loss per share , basic	$ (0.3)	$ (4)	$ (0.93)	$ (11.18)
Net loss per share , diluted	$ (0.3)	$ (4)	$ (0.93)	$ (11.18)
Weighted average shares of common stock outstanding, basic	67,143,744	4,383,131	60,311,003	4,053,341
Weighted average shares of common stock outstanding, diluted	67,143,744	4,383,131	60,311,003	4,053,341

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.